

CURRICULUM VITAE

RAFFAELLA LIONETTI, M.D., PHD

Gastroenterologist and Hepatologist

POIT (Polo Ospedaliero Interaziendale Trapianti)

Istituto Nazionale per le Malattie Infettive "L. Spallanzani"- IRCCS

Rome- Italy

Citizenship: Italian

Language: Italian; English; Spanish

Education

1989-1995 Medical School, University of "la Sapienza" Rome, Italy.

Final mark 110/110 Cum laude

1999-2003 PHD in Methodology and therapy on medicine
prevention, University of Tor Vergata, Rome.

awards

1989 Awarded the American national program on life science
at University of Berkeley, Ca.

Professional experience

- 1993-1995 Pre-doctoral training in Gastroenterology and liver unit,

 Rome university
- 1995-1999 Residency in Gastroenterology and Gastrointestinal
 Endoscopy, University of Rome, Italy. Final mark 70/70 cum
 laude
- Oct 1997-oct 1998 training in liver hemodynamic and transplantation unit
 University of Barcelona , Spain
 .
- 2001-2008 Consultant for the Liver unit and transplant center at Tor
 Vergata University, Rome.
 Diagnostic, therapeutic and emergency endoscopy at Tor
 Vergata University
- 2002- march 2009 consultant for gastroenterology ward and Digestive
 Endoscopy at Fatebenefratelli Clinical hospital,
 Rome, Italy
- April 2009 - present Gastroenterologist/Hepatologist staff member

Department of Infectious disease/hepatology -POIT (Inter –
hospitals transplant center)
National Institute for Infectious Disease “L. Spallanzani”-
IRCCS

2011. present Consultant (hepatology-gastroenterology and
endoscopy) for the US Embassy, Rome

2019 transplant hepatologist graduation

Skills and competence

- Patient caring (gastroenterology, hepatology and gastrointestinal diseases for out-patients office, on duty attendance in the Internal Medicine and Gastroenterology wards)
- Patient caring in the liver transplant setting
- Attendance and endoscopic practice in order to attain endoscopic diagnostic and curative-proficiency in EGD and pancolonoscopy.
- Emergency endoscopy
- Attendance and practice in Hepatic hemodynamic measurements, HVPG measurement, transjugular liver biopsy.
- Laboratory researcher on animal models for liver cirrhosis.

- **Participation in National and International CLINICAL TRIALS: according GSP; GSPcertification already obtained for:**
- **Expanded access program on telaprevir for HCV treatment**
- **BMS AI444-042 daclatasvir for HCV genotype 4 (phase3)**
- **BMS AI 452-020 multicenter randomized , double blind trial, to investigate the efficacy and safety of PEG IFN lambda and ribavirin and telaprevir vs PEGIFN alfa 2 a and ribavirin and telaprevir in naïve or relapse HCV 1 infected patients**
- **A Phase 3, Multicenter, Randomized, Double-Blind,**
- **Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment Naïve and Treatment Experienced Subjects with Chronic Genotype 2 hcv**
- **Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.**
- **Certification refreshed on global health training centre ICH good clinical practice E6 on 19/mar/2020**

- Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
- Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation.
- The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience.
- The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.
- Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
- Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
- A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment

Teaching Experience

- Mentor for GI residents and fellows at Tor Vergata University (Rome) in endoscopy training and clinical hepatology;
- Teaching for Nursing students in Gastroenterology and Hepatology, La Sapienza University (Rome)
- Gastroenterology professor at Unicamillus University

Computer skills :

- Windows operating system and its common tools like microsoft office pack (word processing, spreadsheets, internet browser, slides composition...).
- NCSS program for statistical elaboration data

Scientific Society membership

1995- present AISF (Associazione Italiana per lo Studio del Fegato)
EASL (european association for the study of liver disease)

Languages:

Italian (mother tongue)

Fluent in English and Spanish (written and spoken)

Extra curricula activities:

2011- 2015 reviewer for digestive and liver disease

1. Storia naturale dell'ascite; by Alfa Wassermann in La cirrosi epatica, pag313 to 318
2. La malnutrizione dei pazienti cirrotici, by Il pensiero scientifico, pag 203 a 216 .
3. Hepatic Encephalopathy after transjugular intrahepatic portosystemic shunt: incidence and risk factors. DiG Dis and Sciences ; 1996: 41(3):578-584
4. Does malnutrition affect survival in liver cirrhosis? Hepatology; 1996: 1041-1046
5. Incidence and risk factors of hepatic encephalopathy after TIPS by Record and Al Mardini in Advances in hepatic encephalopathy, pag 279 a 283 .
6. Whole body and regional composition analysis by dual energy X-ray absorptiometry in cirrhotic patients. European Journal of Clinical Nutrition 1997; 51: 810-814
7. Transjugular intrahepatic portosystemic shunt vs endoscopic sclerotherapy for the prevention of variceal rebleeding in cirrhosis: a randomized multicenter trial. Hepatology: 1998; 27: 40-45
8. Cost analysys for the prevention of variceal rebleeding: a comparison between transjugular intrahepatic portosystemic shunt and endoscopic sclerotherapy in a selected group of italian cirrhotic patients. Hepatology 1999; 29; 1074 a 1077

9. Clotting activation after transjugular intrahepatic portosystemic shunt: Thrombosis and Hemostasis 1999; 81: 711-714
10. Ongoing prothrombotic state in portal in the portal circulation of cirrhotic patients. Thrombosis and hemostasis 1997; 77: 44 to 47
11. A new highly effective short-term therapy schedule for helicobacter pylori eradication. Alimentary Pharmacology and therapeutics 2000; 14: 715-718
12. Modification of cardiac function in cirrhotic patients with and without ascites. E American J of Gastroenterology 2000; 95: 320 a 325 e.
13. Effects of blood volume restitution following a portal hypertensive related bleeding in anesthetized cirrhotic rats. Hepatology 2001; 33: 821-825
14. Long acting nitrates. To be or not to be? Digestive and liver disease 2001; 33: 205-211
15. Failure of reinforced triple course of hepatitis B vaccination in patients transplanted for HBV related cirrhosis. Hepatology 2002: 35: 176-181
16. Treatment of primary biliary cirrhosis. gastroenterology international 2001: 14: 84-88
17. Indicazioni al trapianto epatico. Il Policlinico sez Prat 2002; 109: 157-171.
18. Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension. J of Hepatology 2006:1-6
19. Complete weaning of immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J of Hepatology 2006: 44: 702-9
20. A randomized study on PEG IFN alfa 2a with or without ribavirin in liver transplants recipients with recurrent hepatitis C. J of Hepatology 2007: 46: 1009-17,.
21. Large villous adenoma of the appendix: a case treated with sequential endoscopic-minimal surgical technique. Dig liv Dis 2009 Jun; 41: 451-2

22. Maintenance ribavirin monotherapy delays fibrosis in liver transplant recipients with recurrent hepatitis c at high risk of progression. *Dig liv dis* 2010;42 (4) 297-303
23. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. *J Clin Gastroenterol* 2010; 44 (4) 261-6
24. Obscure gastrointestinal bleeding as first symptom of eosinophilic jejunitis in a liver transplant recipient: diagnosis and treatment with single balloon enteroscopy. Urgesi R, Riccioni ME, Nista EC, Lionetti R, Tisone G, Familiari P, Ricci R, Pelecca G, Angelico M, Costamagna G. *BMJ Case Rep.* 2010;2010. doi:pii: bcr05.2009.1918. 10.1136/bcr.05.2009.1918. Epub 2010 Mar 26.
25. Vitamin D3 modulates T lymphocyte responses in hepatitis C virus-infected liver transplant recipients. Almerighi C, Bergamini A, Lionetti R, Sinistro A, Lenci I, Tariciotti L, Tisone G, Angelico M. *Dig Liver Dis.* 2012 Jan;44(1):67-73. doi: 10.1016/j.dld.2011.08.010. Epub 2011 Sep 17
26. Quasispecies tropism and compartmentalization in gut and peripheral blood during early and chronic phases of HIV-1 infection: possible correlation with immune activation markers. Rozera G, Abbate I, Vlassi C, Giombini E, **Lionetti R**, Selleri M, Zaccaro P, Bartolini B, Corpolongo A, D'Offizi G, Baiocchini A, Del Nonno F, Ippolito G, Capobianchi MR. *Clin Microbiol Infect.* 2014 Mar;20(3):O157-66. doi: 10.1111/1469-0691.12367. Epub 2013 Oct 18.
27. A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial. Francioso S, Almerighi C, Forte P, Bandiera F, Nosotti L, **Lionetti R**, Taliani G, Piras MR, Ponti ML, Parruti G, Di Candilo F, Gentile S, Piccolo P, Salso A, Riccobelli F, Renzi S, Longo MA, Montalbano M, Zaru S, Biliotti E, Di Masi

- F, Santopaolo F, Angelico M. Dig Liver Dis. 2014 Feb;46(2):164-9. doi: 10.1016/j.dld.2013.10.002. Epub 2013 Nov 13.
28. Increased plasma concentration of Ribavirin as a result of renal dysfunction in HCV patients treated with telaprevir. Tempestilli M, D'Offizi G, **Lionetti R**, Montalbano M, Giaffreda A, Fazio S, Pucillo LP. Hepatology. 2013 Dec 21. doi: 10.1002/hep.26978. [Epub ahead of print] No abstract available.
29. Laparoscopic liver resections in normal and cirrhotic livers: A retrospective analysis in a tertiary hepato-biliary unit. Ettore GM, Laurenzi A, **Lionetti R**, Santoro R, Lepiane P, Colasanti M, Colace L, Piselli P, Puoti C, D'Offizi G, Antonini M, Vennarecci G. Dig Liver Dis. 2014 Apr;46(4):353-7. doi: 10.1016/j.dld.2013.12.002. Epub 2014 Jan 13.
30. High urine IP-10 levels associate with chronic HCV infection. Petrone L, Chiacchio T, Vanini V, Petruccioli E, Cuzzi G, Di Giacomo C, Pucci L, Montalbano M, **Lionetti R**, Testa A, Lapa D, Navarra A, Visco-Comandini U, Goletti D. J Infect. 2014 Feb 26. pii: S0163-4453(14)00044-9. doi: 10.1016/j.jinf.2014.02.008. [Epub ahead of print]
31. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late. Pellicelli AM, Montalbano M, **Lionetti R**, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M. Dig Liver Dis. 2014 Jul 2. pii: S1590-8658(14)00400-9. doi: 10.1016/j.dld.2014.06.004. [Epub ahead of print]
32. Rapid and preemptive evaluation of individual anti-hepatitis C virus treatment outcome capability by a short-term autologous liver tissue culture system. Cimini E, Bordoni V, Lalle E, Montalbano M, Visco-Comandini U, Taibi C, D'Offizi G, **Lionetti R**, Scognamiglio P, Capobianchi MR, Martini F, Agrati C. New Microbiol. 2014 Jul;37(3):363-7. Epub 2014 Jul 1.

33. Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing. Bartolini B, **Lionetti R**, Giombini E, Sias C, Taibi C, Montalbano M, Gianpiero D, McPhee F, Hughes EA, Zhou N, Ippolito G, Garbuglia AR, Capobianchi MR. *J Clin Virol*. 2015 May;66:38-43. doi: 10.1016/j.jcv.2015.02.001. Epub 2015 Feb 16.
34. Primary and Chronic HIV Infection Differently Modulates Mucosal V δ 1 and V δ 2 T-Cells Differentiation Profile and Effector Functions. Cimini E, Agrati C, D'Offizi G, Vlasi C, Casetti R, Sacchi A, **Lionetti R**, Bordoni V, Tumino N, Scognamiglio P, Martini F. *PLoS One*. 2015 Jun 18;10(6):e0129771. doi: 10.1371/journal.pone.0129771. eCollection 2015.
35. Portal vein aneurysm: What to know. Laurenzi A, Ettore GM, **Lionetti R**, Meniconi RL, Colasanti M, Vennarecci G. *Dig Liver Dis*. 2015 Nov;47(11):918-23. doi: 10.1016/j.dld.2015.06.003. Epub 2015 Jun 19.
36. The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection. Garbuglia AR, **Lionetti R**, Lapa D, Taibi C, Visco-Comandini U, Montalbano M, D'Offizi G, Castiglione F, Capobianchi MR, Paci P. *J Clin Virol*. 2015 Aug;69:68-73. doi: 10.1016/j.jcv.2015.06.002. Epub 2015 Jun 5.
37. Standard bowel cleansing is highly ineffective in cirrhotic patients undergoing screening colonoscopy. Salso A, De Leonardi F, **Lionetti R**, Lenci I, Angelico M, Telese A, Baiocchi L. *Dig Liver Dis*. 2015 Jun;47(6):523-5. doi: 10.1016/j.dld.2015.02.013. Epub 2015 Mar 6.
38. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study. Bartolini B, Selleri M, Garbuglia AR, Giombini E, Taibi C, **Lionetti R**, D'Offizi G, Capobianchi MR. *J Clin Virol*. 2015 Nov;72:60-5. doi: 10.1016/j.jcv.2015.07.310. Epub 2015 Jul 30.

39. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Fontana RJ, Brown RS, Moreno-Zamora A, Prieto M, Joshi S, Londoño MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, **Lionetti R**, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Iltu R, Emond B, Reddy KR.
- a. Liver Transpl. 2016 Feb 17. doi: 10.1002/lt.24416. [Epub ahead of print]
40. Endoscopic management with multiple plastic stents of anastomotic biliary stricture following liver transplantation: long-term results.
- a. Tringali A, Barbaro F, Pizzicannella M, Boškoski I, Familiari P, Perri V, Gigante G, Onder G, Hassan C, **Lionetti R**, Ettorre GM, Costamagna G. Endoscopy. 2016 Feb 9. [Epub ahead of print]
41. Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. Ponziani FR, Siciliano M, **Lionetti R**, Pasquazzi C, Gianserra L, D'Offizi G, Gasbarrini A, Pompili M. Am J Kidney Dis. 2017 Mar 1. pii: S0272-6386(17)30112-9. doi:
42. Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection. D'Offizi G, Cammà C, Taibi C, Schlag M, Weber K, Palma M, DeMasi R, Janssen K, Witek J, **Lionetti R**. New Microbiol. 2017 Jan;40(1):19-26. Epub 2017 Jan 9.
43. Simple and Reliable Method to Quantify the Hepatitis B Viral Load and Replicative Capacity in Liver Tissue and Blood Leukocytes. Minosse C, Coen S, Visco Comandini U, **Lionetti R**, Montalbano M, Cerilli S, Vincenti D, Baiocchini A, Capobianchi MR, Menzo S. Hepat Mon. 2016 Feb 29;16(10):e28751. eCollection 2016 Oct.

44. Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors. Garbuglia AR, Visco-Comandini U, **Lionetti R**, Lapa D, Castiglione F, D'Offizi G, Taibi C, Montalbano M, Capobianchi MR, Paci P. *PLoS One*. 2016 Aug 25;11(8):e0158989. doi: 10.1371/journal.pone.0158989. eCollection 2016.
45. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. Ettore GM, Levi Sandri GB, Laurenzi A, Colasanti M, Meniconi RL, **Lionetti R**, Santoro R, Lepiane P, Sciuto R, Pizzi G, Cianni R, Golfieri R, D'Offizi G, Pellicelli AM, Antonini M, Vennarecci G. *World J Surg*. 2017 Jan;41(1):241-249. doi: 10.1007/s00268-016-3682-z.
46. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. *Lancet Gastroenterol Hepatol*. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10.
47. Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients. *Clin Immunol*. 2017 Oct;183:82-90. doi: 10.1016/j.clim.2017.07.017. Epub 2017 Jul 20. Sacchi A, Tumino N, Turchi F, Refolo G, Fimia G, Ciccocanti F, Montalbano M, Lionetti R, Taibi C, D'Offizi G, Casetti R, Bordoni V, Cimini E, Martini F, Agrati.
48. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. Bartolini B, Giombini E, Taibi C, Lionetti R, Montalbano

- M, Visco-Comandini U, D'Offizi G, Capobianchi MR, McPhee F, Garbuglia AR. *Viruses*. 2017 Aug 7;9(8). pii: E212. doi: 10.3390/v9080212.
49. The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience. Carrai P, Morelli C, Cordone G, Romano A, Tamé M, Lionetti R, Pietrosi G, Lenci I, Piai G, Russo FP, Coppola C, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Martini S, Toniutto P; ITACOPS study group.
- a. *Transpl Int*. 2017 Dec;30(12):1253-1265. doi: 10.1111/tri.13018. Epub 2017 Sep 7.
50. The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Martini S, Donato MF, Mazzarelli C, Rendina M, Visco-Comandini U, Fili D, Gianstefani A, Faggioli S, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Carrai P, Caraceni P; ITACOPS study group. *Liver Int*. 2018 Apr;38(4):733-741. doi: 10.1111/liv.13588. Epub 2017 Oct .
51. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. *Clin Transplant*. 2018 Feb;32(2). doi: 10.1111/ctr.13165. Epub 2017 Dec 18. Lionetti R, Calvaruso V, Piccolo P, Mancusi RL, Mazzarelli C, Faggioli S, Montalbano M, Lenci I, Carrai P, Guaraldi G, Visco-Comandini U, Milana M, Biolato M, Loiacono L, Valente G, Craxì A, Angelico M, D'offizi G.
52. Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols. Visco-Comandini U, Lapa D, Lionetti R, Taibi C, Loiacono L, Montalbano M, Capobianchi MR, D'Offizi G, Garbuglia AR. *J Med Virol*. 2018 Jul;90(7):1264-1271. doi: 10.1002/jmv.25084. Epub 2018 Apr 26..

53. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. Lanini S, Scognamiglio P, Mecozzi A, Lombardozi L, Vullo V, Angelico M, Gasbarrini A, Taliani G, Attili AF, Perno CF, De Santis A, Puro V, Cerqua F, D'Offizi G, Pellicelli A, Armignacco O, Mennini FS, Siciliano M, Girardi E, Panella V, Ippolito G; members of the Lazio Region HCV treatment group.
- a. BMC Infect Dis. 2018 May 16;18(1):223. doi: 10.1186/s12879-018-3125-.
54. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
- a. Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzoni M, Giannini EG, Craxì A; ABACUS Study Group. Infection. 2018 May 28. doi: 10.1007/s15010-018-1157-x. [Epub ahead of print]
55. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
- a. Masetti C, Lionetti R, Lupo M, Siciliano M, Giannelli V, Ponziani FR, Teti E, Dell'Unto C, Francioso S, Brega A, Montalbano M, Visco-Comandini U, Taibi C, Galati G, Vespasiani Gentilucci U, Picardi A, Andreoni M, Pompili M, Pellicelli AM, D'Offizi G, Gasbarrini A, De Santis A, Angelico M. J Viral Hepat. 2018 Dec;25(12):1493-1500. doi: 10.1111/jvh.12982. Epub 2018 Sep 6.
56. Pitfalls in the reporting of upper endoscopy features in cirrhotic patients.
- a. Cucchiarelli S, Santopaolo F, Lamazza A, Lionetti R, Lenci I, Manzia TM, Angelico M, Milana M, Baiocchi L. Dig Liver Dis. 2018

Aug 18. pii: S1590-8658(18)30895-8. doi:
10.1016/j.dld.2018.08.014. [Epub ahead of print]

57. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group. *Pharmacoeconomics*. 2019 Feb;37(2):255-266. doi: 10.1007/s40273-018-0733-3.
58. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. Calvaruso V, Mazzarelli C, Milazzo L, Badia L, Pasulo L, Guaraldi G, **Lionetti R**, Villa E, Borghi V, Carrai P, Alberti A, Biolato M, Piai G, Persico M, Santantonio T, Felder M, Angelico M, Montalbano M, Mancusi RL, Grieco A, Angeli E, D'Offizi G, Faggiuoli S, Belli L, Verucchi G, Puoti M, Craxì A. *Sci Rep*. 2019 Jan 24;9(1):585. doi: 10.1038/s41598-018-36734-0.
59. Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. Lionetti R, Piccolo P, Lenci I, Siciliano M, Visco-Comandini U, De Santis A, Pompili M, Milana M, Taibi C, Dell'Isola S, Montalbano M, Mastroianni C, Begini P, Garbuglia AR, Angelico M, D'Offizi G. *Ann Hepatol*. 2019 May - Jun;18(3):434-438. doi: 10.1016/j.aohep.2018.09.005. Epub 2019 Apr 15.
60. Increased cancer risk in patients undergoing dialysis: a population-based cohort study in North-Eastern Italy. Taborelli M, Toffolutti F, Del Zotto S, Clagnan E, Furian L, Piselli P, Citterio F, Zanier L, Boscutti G, Serraino D; Italian Transplant & Cancer Cohort Study. *BMC Nephrol*. 2019 Mar 28;20(1):107. doi: 10.1186/s12882-019-1283-4.

61. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. *Pharmacoeconomics*. 2019 Feb;37(2):255-266. doi: 10.1007/s40273-018-0733-3. Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at www.progettopiter.it. *Pharmacoeconomics*. 2019 Feb;37(2):255-266. doi: 10.1007/s40273-018-0733-3.
62. The impact of the coronavirus disease 2019 pandemic on a central Italy transplant center. Montalbano M, Levi Sandri GB, Visco Comandini U, Lionetti R, Vincenzi L, Berardi G, Guglielmo N, Pellicelli A, Ettorre GM, D'Offizi G. *Medicine (Baltimore)*. 2020 Oct 9;99(41):e22174.
63. Cumulative incidence of solid and hematological De novo malignancy after liver transplantation in a multicentre cohort. Lucidi C, Biolato M, Lai Q, Lattanzi B, Lenci I, Milana M, Lionetti R, Liguori A, Angelico M, Tisone G, Avolio AW, Agnes S, Rossi M, Grieco A, Merli M. *Ann Hepatol* 2021 Jan 20;24:100309. doi: 10.1016/j.aohp.2021.100309.
64. Anti-HEV IgG Avidity Testing: Utility for Diagnosing Acute and Resolved Genotype 3 Infections. Minosse C, Lapa D, Coppola A, Rapagna F, D'Offizi G, Taibi C, Lionetti R, Capobianchi MR, McPhee F, Garbuglia AR. *Viruses*. 2021 Feb 3;13(2):236. doi: 10.3390/v13020236. PMID: 33546482; PMCID: PMC7913725.
65. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. Mondì A, Lorenzini P, Castilletti C, Gagliardini R, Lalle E, Corpolongo A, Valli MB, Taglietti F, Cicalini S, Loiacono L, Di Gennaro F, D'Offizi G, Palmieri F, Nicastrì E, Agrati C, Petrosillo N, Ippolito

G, Vaia F, Girardi E, Capobianchi MR, Antinori A, Zito S, Abbonizio MA, Abdeddaim A, Agostini E, Agrati C, Albarello F, Amadei G, Amendola A, Antinori A, Antonica MA, Antonini M, Bartoli TA, Baldini F, Barbaro R, Bartolini B, Bellagamba R, Benigni M, Bevilacqua N, Biava G, Bibas M, Bordi L, Bordoni V, Boumis E, Branca M, Buonomo R, Busso D, Camici M, Campioni P, Canichella F, Capobianchi MR, Capone A, Caporale C, Caraffa E, Caravella I, Carletti F, Castilletti C, Cataldo A, Cerilli S, Cerva C, Chiappini R, Chinello P, Cianfarani MA, Ciaralli C, Cimaglia C, Cinicola N, Ciotti V, Cicalini S, Colavita F, Corpolongo A, Cristofaro M, Curiale S, D'Abramo A, Dantimi C, De Angelis A, De Angelis G, De Palo MG, De Zottis F, Di Bari V, Di Lorenzo R, Di Stefano F, D'Offizi G, Donno D, Evangelista F, Faraglia F, Farina A, Ferraro F, Fiorentini L, Frustaci A, Fusetti M, Galati V, Gagliardini R, Gallì P, Garotto G, Gaviano I, Tekle SG, Giancola ML, Giansante F, Giombini E, Granata G, Greci MC, Grilli E, Grisetti S, Gualano G, Iacomì F, Iaconi M, Iannicelli G, Inversi C, Ippolito G, Lalle E, Lamanna ME, Lanini S, Lapa D, Lepore L, Libertone R, Lionetti R, Liuzzi G, Loiacono L, Lucia A, Lufrani F, Macchione M, Maffongelli G, Marani A, Marchioni L, Mariano A, Marini MC, Maritti M, Mastrobattista A, Mastrorosa I, Matusali G, Mazzotta V, Mencarini P, Meschi S, Messina F, Micarelli S, Mogavero G, Mondì A, Montalbano M, Montaldo C, Mosti S, Murachelli S, Musso M, Nardi M, Navarra A, Nicastrì E, Nocioni M, Noto P, Noto R, Oliva A, Onnis I, Ottou S, Palazzolo C, Pallini E, Palmieri F, Palombi G, Pareo C, Passeri V, Pelliccioni F, Penna G, Petrecchia A, Petrone A, Petrosillo N, Pianura E, Pinnetti C, Pisciotta M, Piselli P, Pittalis S, Pontarelli A, Proietti C, Puro V, Ramazzini PM, Rianda A, Rinonapoli G, Rosati S, Rubino D, Rueca M, Ruggeri A,

- Sacchi A, Sampaolesi A, Sanasi F, Santagata C, Scarabello A, Scarcia S, Schininà V, Scognamiglio P, Scorzolini L, Stazi G, Strano G, Taglietti F, Taibi C, Taloni G, Nardi T, Tonnarini R, Topino S, Tozzi M, Vaia F, Vairo F, Valli MB, Vergori A, Vincenzi L, Visco-Comandini U, Vita S, Vittozzi P, Zaccarelli M, Zanetti A, Zito S; INMI Recovery study group.. *Int J Infect Dis.* 2021 Apr;105:532-539. doi: 10.1016/j.ijid.2021.02.117. Epub 2021 Mar 3. PMID: 33676001; PMCID: PMC7927669.
66. Sarco-Model Study Group. Sarco-Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation . Lai Q, Magistri P, Lionetti R, Avolio AW, Lenci I, Giannelli V, Pecchi A, Ferri F, Marrone G, Angelico M, Milana M, Schinninà V, Menozzi R, Di Martino M, Grieco A, Manzia TM, Tisone G, Agnes S, Rossi M, Di Benedetto F, Ettorre GM;. *Liver Int.* 2021 Jul;41(7):1629-1640. doi: 10.1111/liv.14889. Epub 2021 Apr 22. PMID: 33793054.
67. Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia. Vergori A, Lorenzini P, Cozzi-Lepri A, Donno DR, Gualano G, Nicastrì E, Iacomi F, Marchioni L, Campioni P, Schininà V, Cicalini S, Agrati C, Capobianchi MR, Girardi E, Ippolito G, Vaia F, Petrosillo N, Antinori A, Taglietti F; ReCOVeRI Study Group.. *Sci Rep.* 2021 May 31;11(1):11334. doi: 10.1038/s41598-021-90713-6. PMID: 34059708; PMCID: PMC8167179.

speakers

- Relatore corso Nuovi DAA ed EAP per epatite C, gennaio 2013, INMI
- Relatore corso DAA, trattamento HCV, anche io voglio guarire, Roma, Maggio 2013

- Relatore trisocietario regionale Roma Novembre 2013, il web referral per il trapianto epatico.
- Relatore corso Oltre la fibrosi, le nuove frontiere terapeutiche, Roma Dicembre 2013, INMI
- dicembre
- Relatore incontro regionale DAA, Roma febbraio 2014
- Relatore il salotto dell'epatologia, Grottaferrata Maggio 2014
- Relatore HCV obiettivo eradicazione, Giugno 2014
- Relatore HBV e ospite immunocompromesso Giugno 2014, Roma
- Relatore dal referral al trapianto; terapia antivirale nel post trapianto; passato, presente e futuro, Roma settembre 2014 INMI
- Relatore Hot topics in hepatology PTV settembre 2015, TARE
- Relatore dal referral al trapianto novembre 2015, setting terapia HCv nel percorso OLT
- Relatore mercoledì' dei trapianti, ottobre 2015: cirrosi ed infezioni nel percorso trapiantologico
- Relatore Hepic, Roma 13 maggio 2016.
- Relatore What's new in clinical hepatology ; Roma PTV settembre 2016
- Relatore 29 Novembre 2016 Roma Life style hotel, advancing hepatitis C for the optimization of cure
- Relatore mercoledì dei trapianti dicembre 2016, indicazioni a trapianto epatico.
- Relatore What's new in clinical hepatology ; Roma PTV settembre 2017
- Relatore mercoledì dei trapianti ottobre 2017, incontro italo-francese: nuovi criteri di allocazione per CRT
- Relatore salotto dell'epatologia; grottaferrata Dicembre 2017
- Relatore real life experience in HCV, roma 12 giugno 2018

- Relatore mercoledì dei trapianti ottobre 2018, terapia con DAAs nei pazienti HCV e OLT
- Relatore mercoledì dei trapianti aprile 2019, insufficienza epatica acuta virale e giugno 2019 gestione delle infezioni multiresistenti nel donatore
- Relatore epa Day, Roma 11 maggio 2019
- Relatore I percorsi diagnostici delle epatiti virali alla luce dei cambiamenti terapeutici ed epidemiologici: ultimi aggiornamenti su HCV, Roma 9 maggio 2019
- Relatore INMi lazzaro spallanzani 1 giugno 2019: Curare l'epatite da HCV: regimi terapeutici e ruolo del test & treat
- Relatore INMi lazzaro spallanzani giugno 2021, mercoledì dei trapianti: covid e immunosoppressione nel trapianto

Raffaella Lionetti M.D.